CAJ | 학술논문

目的：探讨血清胱抑素（Cys-C）与慢性阻塞性肺疾病继发肺动脉高压相关性。方法回顾性分析2012年9月至2014年1月皖南医学院第一附属医院呼吸科慢性阻塞性肺疾病144例住院患者的临床资料。将144例入选病例分为肺动脉压正常组和增高组，比较两组一般情况、基础疾病情况、Cys-C和住院时间。结果肺动脉压增高组Cys-C明显高于肺动脉压正常组Cys-C （0.97±0.43 vs 1.22±0.36），差异有统计学意义（P＜0.001）。而年龄、性别、高血压、糖尿病、冠心病、PaO2、PaCO2及住院时间两组差异均无统计学意义（P＞0.05）。Pearson相关性分析结果示Cys-C与肺动脉高压呈正相关性（r＝0.614，P＜0.01）。结论慢阻肺继发肺动脉高压患者体内Cys-C明显增高，并与肺动脉高压严重程度呈正相关。Cys-C可作为反应慢性阻塞性肺疾病继发肺动脉高压严重程度的指标。
목적：탐토혈청광억소（Cys-C）여만성조새성폐질병계발폐동맥고압상관성。방법회고성분석2012년9월지2014년1월환남의학원제일부속의원호흡과만성조새성폐질병144례주원환자적림상자료。장144례입선병례분위폐동맥압정상조화증고조，비교량조일반정황、기출질병정황、Cys-C화주원시간。결과폐동맥압증고조Cys-C명현고우폐동맥압정상조Cys-C （0.97±0.43 vs 1.22±0.36），차이유통계학의의（P＜0.001）。이년령、성별、고혈압、당뇨병、관심병、PaO2、PaCO2급주원시간량조차이균무통계학의의（P＞0.05）。Pearson상관성분석결과시Cys-C여폐동맥고압정정상관성（r＝0.614，P＜0.01）。결론만조폐계발폐동맥고압환자체내Cys-C명현증고，병여폐동맥고압엄중정도정정상관。Cys-C가작위반응만성조새성폐질병계발폐동맥고압엄중정도적지표。
Objective To explore the relationship between serum cystatin C (Cys-C)and pulmonary hypertension secondary to chro-nic obstructive pulmonary disease (COPD).Methods The clinical data of 144 inpatients with COPD in our hospital from Sep 2012 to Jan 2014 was retrospective analyzed.All cases were divided into hypertension group and normal group according to the pulmonary artery pressure. General conditions,underlying diseases,serum Cys-C and hospital stays of patients in the two groups were compared separately.Results Serum Cys-C concentration in the hypertension group was much higher than that of the normal group (0.97 ±0.43 vs 1.22 ±0.36),and the difference between the two groups was statistically significant (P<0.001).However,there was no significant difference in the age,sex,hy-pertension,diabetes,coronary heart disease,PaO2 ,PaCO2 and hospital stays of both groups.Pearson correlation analysis showed that serum Cys-C was positively related to pulmonary hypertension (r=0.614,P<0.01).Conclusion The serum Cys-C concentration increases sig-nificantly in patients with pulmonary hypertension secondary to COPD,and shared positive correlation with the severity of pulmonary hyperten-sion.It is reasonable to use Cys-C as a index to evaluate the severity of pulmonary hypertension secondary to COPD.